Cargando…

Nationwide Long-Term Evaluation of Polypharmacy Reduction Policies Focusing on Older Adults in Japan

Polypharmacy is a serious health issue for older adults worldwide, including in Japan, which has a rapidly aging society. The “Proper Medication Guideline for Older Adults” was published for healthcare providers in May 2018, and polypharmacy reduction incentives were initiated for medical facilities...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishida, Takehiro, Suzuki, Asuka, Nakata, Yoshinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691254/
https://www.ncbi.nlm.nih.gov/pubmed/36429409
http://dx.doi.org/10.3390/ijerph192214684
_version_ 1784836999404847104
author Ishida, Takehiro
Suzuki, Asuka
Nakata, Yoshinori
author_facet Ishida, Takehiro
Suzuki, Asuka
Nakata, Yoshinori
author_sort Ishida, Takehiro
collection PubMed
description Polypharmacy is a serious health issue for older adults worldwide, including in Japan, which has a rapidly aging society. The “Proper Medication Guideline for Older Adults” was published for healthcare providers in May 2018, and polypharmacy reduction incentives were initiated for medical facilities in April 2016 and April 2018. This study identified the long-term reduction in polypharmacy prescriptions focusing on older adults aged 75 years and above from April 2015 to March 2019. The national health insurance claims database, which covers most reimbursement claims in Japan, was selected as the primary data source. In this study, polypharmacy was defined as the simultaneous prescription of seven or more medications or multi-psychotropic medications. The primary outcome was the polypharmacy reduction ratio, which indicates the decrease in polypharmacy proportion based on the number of medications on an outpatient prescription. A total polypharmacy reduction of 19.3% for the “75–89 years” subgroup and 16.5% for the “90 years and above” subgroup was observed over four years. Based on prefecture analysis, the mean values of polypharmacy proportion showed a statistically significant reduction over four years. This study showed a successful nationwide reduction in polypharmacy prescriptions after implementing the polypharmacy management guidelines for older adults and incentive-based policies.
format Online
Article
Text
id pubmed-9691254
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96912542022-11-25 Nationwide Long-Term Evaluation of Polypharmacy Reduction Policies Focusing on Older Adults in Japan Ishida, Takehiro Suzuki, Asuka Nakata, Yoshinori Int J Environ Res Public Health Article Polypharmacy is a serious health issue for older adults worldwide, including in Japan, which has a rapidly aging society. The “Proper Medication Guideline for Older Adults” was published for healthcare providers in May 2018, and polypharmacy reduction incentives were initiated for medical facilities in April 2016 and April 2018. This study identified the long-term reduction in polypharmacy prescriptions focusing on older adults aged 75 years and above from April 2015 to March 2019. The national health insurance claims database, which covers most reimbursement claims in Japan, was selected as the primary data source. In this study, polypharmacy was defined as the simultaneous prescription of seven or more medications or multi-psychotropic medications. The primary outcome was the polypharmacy reduction ratio, which indicates the decrease in polypharmacy proportion based on the number of medications on an outpatient prescription. A total polypharmacy reduction of 19.3% for the “75–89 years” subgroup and 16.5% for the “90 years and above” subgroup was observed over four years. Based on prefecture analysis, the mean values of polypharmacy proportion showed a statistically significant reduction over four years. This study showed a successful nationwide reduction in polypharmacy prescriptions after implementing the polypharmacy management guidelines for older adults and incentive-based policies. MDPI 2022-11-09 /pmc/articles/PMC9691254/ /pubmed/36429409 http://dx.doi.org/10.3390/ijerph192214684 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ishida, Takehiro
Suzuki, Asuka
Nakata, Yoshinori
Nationwide Long-Term Evaluation of Polypharmacy Reduction Policies Focusing on Older Adults in Japan
title Nationwide Long-Term Evaluation of Polypharmacy Reduction Policies Focusing on Older Adults in Japan
title_full Nationwide Long-Term Evaluation of Polypharmacy Reduction Policies Focusing on Older Adults in Japan
title_fullStr Nationwide Long-Term Evaluation of Polypharmacy Reduction Policies Focusing on Older Adults in Japan
title_full_unstemmed Nationwide Long-Term Evaluation of Polypharmacy Reduction Policies Focusing on Older Adults in Japan
title_short Nationwide Long-Term Evaluation of Polypharmacy Reduction Policies Focusing on Older Adults in Japan
title_sort nationwide long-term evaluation of polypharmacy reduction policies focusing on older adults in japan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691254/
https://www.ncbi.nlm.nih.gov/pubmed/36429409
http://dx.doi.org/10.3390/ijerph192214684
work_keys_str_mv AT ishidatakehiro nationwidelongtermevaluationofpolypharmacyreductionpoliciesfocusingonolderadultsinjapan
AT suzukiasuka nationwidelongtermevaluationofpolypharmacyreductionpoliciesfocusingonolderadultsinjapan
AT nakatayoshinori nationwidelongtermevaluationofpolypharmacyreductionpoliciesfocusingonolderadultsinjapan